Skip to main navigation menu Skip to main content Skip to site footer

Technical comment

Vol. 141 No. 4142 (2011)

Letter to the editor

  • O Tanriverdi
  • D Cetin
DOI
https://doi.org/10.4414/smw.2011.13257
Cite this as:
Swiss Med Wkly. 2011;141:w13257
Published
10.10.2011

References

  1. Yavas O, Yazici M, Eren O, Oyan B. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Swiss Med Wkly. 2007;137(39-40):556‒8 http://www.smw.ch/docs/pdf200x/2007/39/smw-11899.PDF.
  2. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin adjuvant (HERA) trial. J Clin Oncol. 2010;28(21):3422‒ 8.
  3. Telli ML, Witteles RM. Trastuzumab-related cardiac dysfunction. J Natl Compr Canc Netw. 2011;9(2):243‒9.
  4. Yelamanchi VP, Molnar J, Ranade V, Somberg JC. Influence of electrolyte abnormalities on interlead variability of ventricular repolarization times in 12-lead electrocardiography. Am J Ther. 2001;8(2):117‒22.